Human Stem Cells Institute's RAS net income for 9M 2021 was ₽47.707 million, up 46.2% from ₽32.632 million in the previous year. Revenue increased 19.4% to ₽50.682 million compared to ₽42.459 million a year earlier.

HSCI has begun Phase I-II clinical trials for the coronavirus vaccine Betuvax-CoV-2. The drug will be tested on 170 volunteers between the ages of 18 and 60. Participants will receive two components of the vaccine at 28-day intervals. The developers expect minimal side effects due to the characteristics of the composition. According to preclinical studies, t...

HSCI has received approval from the Russian Ministry of Health to begin clinical trials of the coronavirus vaccine Betuvax-CoV-2. The drug consists of nanoparticles that mimic the SARS-CoV-2 coronavirus but are not capable of infecting mammals. Phase I and Phase II trials will run from September 27, 2021 to August 31, 2022.

Board of Directors of Human Stem Cells Institute set the offering price of additional common shares at ₽80 per share. The company intends to place 12,500,000 shares by private subscription in favor of the International Medical Center for Biomaterials Processing and Cryopreservation.